AQR Capital Management
PRTK

AQR Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

AQR Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-26,115
Closed -$178K – 2362
2021
Q2 		$178K Sell
26,115
-6,511
-20% -$52.6K ﹤0.01% 2151
2021
Q1 		$230K Hold
32,626
– – ﹤0.01% 2076
2020
Q4 		$204K Buy
32,626
+1,630
+5% +$9.59K ﹤0.01% 2087
2020
Q3 		$168K Buy
30,996
+18,719
+152% +$92.7K ﹤0.01% 2087
2020
Q2 		$64K Buy
+12,277
New +$54.5K ﹤0.01% 2078
2018
Q2 		– Sell
-12,789
Closed -$166K – 2401
2018
Q1 		$166K Sell
12,789
-5,642
-31% -$84K ﹤0.01% 2170
2017
Q4 		$330K Hold
18,431
– – ﹤0.01% 2042
2017
Q3 		$463K Buy
+18,431
New +$429K ﹤0.01% 1969
2014
Q3 		– Sell
-17,443
Closed -$417K – 2611
2014
Q2 		$417K Hold
17,443
– – ﹤0.01% 2074
2014
Q1 		$645K Hold
17,443
– – ﹤0.01% 1920
2013
Q4 		$703K Buy
17,443
+14,717
+540% +$625K ﹤0.01% 1892
2013
Q3 		$104K Buy
+2,726
New +$97.6K ﹤0.01% 2424

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's PRTK Position: Q3 2021 in Review

AQR Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 26,115 shares — an estimated $178K sold.

AQR Capital Management first reported a position in PRTK in Q3 2013 and held it in 12 quarters. The position peaked at $703K in Q4 2013. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • AQR Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • AQR Capital Management sold 26,115 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $178K.
  • AQR Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and held it in 12 quarters.
  • AQR Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $703K in Q4 2013.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on AQR Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.